Autologous haematopoietic stem cell transplantation for immune-mediated neurological diseases: what, how, who and why?
Brittain, Gavin Coles, Alasdair Muraro, Paolo Palace, Jacqueline Petrie, Jennifer Roldan, Elisa Snowden, John Sharrack, Basil
Brittain, Gavin
Coles, Alasdair
Muraro, Paolo
Palace, Jacqueline
Petrie, Jennifer
Roldan, Elisa
Snowden, John
Sharrack, Basil
Glos Author
Date
2022-09-26
Journal Title
Subject
Type
Journal Article
Collections
Abstract
In carefully selected patients, autologous haematopoietic stem cell transplantation (HSCT) is a safe, highly effective and cost-saving treatment modality for treatment-resistant, and potentially treatment-naïve, immune-mediated neurological disorders. Although the evidence base has been growing in the last decade, limited understanding has led to confusion, mistrust and increasing use of health tourism. In this article, we discuss what autologous HSCT is, which immune-mediated conditions can be treated with it, how to select patients, what are the expected outcomes and potential adverse effects, and how cost-effective this treatment is.
Citation
Brittain, G., Coles, A. J., Giovannoni, G., Muraro, P. A., Palace, J., Petrie, J., Roldan, E., Scolding, N. J., Snowden, J. A., & Sharrack, B. (2023). Autologous haematopoietic stem cell transplantation for immunemediated neurological diseases: what, how, who and why? Practical Neurology, 23(2), 139–145. https://doi.org/10.1136/pn-2022-003531